MedTrace Logo

Patient Convenience Study- NIS RELATE

NCT02849509 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1313

Last updated 2019-07-08

Study results available
· View outcomes & findings →

Summary

The aim of this non-interventional study is to describe patient's perception of anticoagulant treatment when using Pradaxa® to prevent stroke and systemic embolism while suffering from atrial fibrillation (according to its approved indication in the approved dosages of 110 mg or 150 mg twice daily) in comparison to standard care using Vitamin K Antagonist (VKA).

Conditions

Interventions

DRUG

Pradaxa (dabigatran)

Pradaxa (dabigatran etexilate)110mg or 150mg

DRUG

Vitamin K antagonist

Vitamin K antagonist or Pradaxa

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-20
Primary Completion
2017-12-30
Completion
2017-12-30

Countries

  • Indonesia
  • Malaysia
  • Singapore
  • South Korea
  • Thailand

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02849509 on ClinicalTrials.gov